Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Several other equities research analysts have also recently weighed in on DMRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Guggenheim lifted their price objective on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Finally, Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $46.50.
Read Our Latest Research Report on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock Price Performance
Damora Therapeutics, Inc. Common Stock stock opened at $21.49 on Friday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $4.95 and a 12-month high of $38.33. The firm has a 50 day simple moving average of $23.53 and a 200-day simple moving average of $25.76. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.38 and a beta of 1.52.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.
Insider Buying and Selling at Damora Therapeutics, Inc. Common Stock
In other news, CEO Jennifer Jarrett purchased 12,500 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were purchased at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.40% of the company’s stock.
Institutional Trading of Damora Therapeutics, Inc. Common Stock
Several large investors have recently added to or reduced their stakes in DMRA. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth about $260,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter worth about $7,398,000. Finally, Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $42,146,000. 14.20% of the stock is owned by institutional investors and hedge funds.
About Damora Therapeutics, Inc. Common Stock
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
See Also
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
